IMMIX BIOPHARMA, INC. Stock-Based Compensation
IMMIX BIOPHARMA, INC. (IMMX) reported Stock-Based Compensation of $1.55 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $978.14K, a 83.77% increase year-over-year.
- IMMIX BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $575.57K, a 33.72% decline year-over-year.
- IMMIX BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $570.80K, a 19.11% decline year-over-year.
- IMMIX BIOPHARMA, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $470.47K, a 35.89% decline year-over-year.
- IMMIX BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $2.44M, a 19.16% decline from fiscal 2024.
- IMMIX BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $3.02M, a 17.73% increase from fiscal 2023.
- IMMIX BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $2.57M, a 311.13% increase from fiscal 2022.
- IMMIX BIOPHARMA, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $624.07K, a 184.99% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $978.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.55M 10-Q · filed 2026-08-07 | $2.12M derived: sum of 3 quarters · filed 2026-08-07 | $2.59M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2026-03-31 | $575.57K 10-Q · filed 2026-05-07 | $1.15M derived: sum of 2 quarters · filed 2026-05-07 | $1.62M derived: sum of 3 quarters · filed 2026-05-07 | $2.15M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-12-31 | $570.80K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | $1.04M derived: sum of 2 quarters · filed 2026-03-27 | $1.57M derived: sum of 3 quarters · filed 2026-08-07 | $2.44M 10-K/A · filed 2026-03-27 | |||
| 2025-09-30 | $470.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.00M derived: sum of 2 quarters · filed 2026-08-07 | $1.87M 10-Q · filed 2025-11-07 | $2.58M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-06-30 | $532.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $1.40M 10-Q · filed 2026-08-07 | $2.11M derived: sum of 3 quarters · filed 2026-08-07 | $2.84M derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-03-31 | $868.36K 10-Q · filed 2026-05-07 | $1.57M derived: sum of 2 quarters · filed 2026-05-07 | $2.31M derived: sum of 3 quarters · filed 2026-05-07 | $2.95M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $705.65K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | $1.44M derived: sum of 2 quarters · filed 2026-03-27 | $2.08M derived: sum of 3 quarters · filed 2026-03-27 | $3.02M 10-K/A · filed 2026-03-27 | |||
| 2024-09-30 | $733.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.37M derived: sum of 2 quarters · filed 2025-11-07 | $2.31M 10-Q · filed 2025-11-07 | $3.37M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | $637.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $1.58M 10-Q · filed 2025-08-08 | $2.63M derived: sum of 3 quarters · filed 2025-08-08 | $3.37M derived: sum of 4 quarters · filed 2025-08-08 | |||
| 2024-03-31 | $943.26K 10-Q · filed 2025-05-08 | $1.99M derived: sum of 2 quarters · filed 2025-05-08 | $2.73M derived: sum of 3 quarters · filed 2025-05-08 | $3.18M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $1.79M derived: sum of 2 quarters · filed 2025-03-25 | $2.24M derived: sum of 3 quarters · filed 2025-03-25 | $2.57M 10-K · filed 2025-03-25 | |||
| 2023-09-30 | $737.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.18M derived: sum of 2 quarters · filed 2024-11-12 | $1.51M 10-Q · filed 2024-11-12 | $1.74M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $447.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $777.58K 10-Q · filed 2024-08-12 | $1.01M derived: sum of 3 quarters · filed 2024-08-12 | $1.22M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | $329.92K 10-Q · filed 2024-05-09 | $560.01K derived: sum of 2 quarters · filed 2024-05-09 | $773.21K derived: sum of 3 quarters · filed 2024-05-09 | $888.91K derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $230.09K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $443.29K derived: sum of 2 quarters · filed 2024-03-29 | $559.00K derived: sum of 3 quarters · filed 2024-03-29 | $624.07K 10-K · filed 2024-03-29 | $524.07K 10-K · filed 2023-03-27 | ||
| 2022-09-30 | $213.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $328.90K derived: sum of 2 quarters · filed 2023-11-13 | $393.98K 10-Q · filed 2023-11-13 | $293.98K 10-Q · filed 2022-11-09 | $516.13K derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $115.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $180.78K 10-Q · filed 2023-08-11 | $130.78K 10-Q · filed 2022-08-12 | $302.94K derived: sum of 3 quarters · filed 2023-08-11 | $364.80K derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | $65.07K 10-Q · filed 2023-05-12 | $187.23K derived: sum of 2 quarters · filed 2023-05-12 | $249.09K derived: sum of 3 quarters · filed 2023-05-12 | $279.81K derived: sum of 4 quarters · filed 2023-05-12 | |||
| 2021-12-31 | $122.15K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $184.01K derived: sum of 2 quarters · filed 2023-03-27 | $214.74K derived: sum of 3 quarters · filed 2023-03-27 | $218.98K 10-K · filed 2023-03-27 | |||
| 2021-09-30 | $61.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $92.58K derived: sum of 2 quarters · filed 2022-11-09 | $96.83K 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | $30.72K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $34.97K 10-Q · filed 2022-08-12 | |||||
| 2021-03-31 | $4.25K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |